US Patent Issued to RemeGen on July 7 for "Use of anti-HER2 antibody-drug conjugate in treating urothelial carcinoma" (Chinese Inventor)

ALEXANDRIA, Va., July 7 -- United States Patent no. 12,673,110, issued on July 7, was assigned to RemeGen Co. Ltd. (Yantai, China).

"Use of anti-HER2 antibody-drug conjugate in treating urothelial carcinoma" was invented by Jianmin Fang (Yantai, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the use of an anti-HER2 antibody-drug conjugate (ADC) in preparing a drug for treating urothelial carcinoma. The drug is safe and effective for patients with urothelial carcinoma, especially locally advanced or metastatic urothelial carcinoma, and can effectively prolong the survival time of the patients."

The patent was filed on Aug. 19, 2019, under Application No. 16/652,413.

*F...